Ortho-K vs. Atropine vs. MiSight: Which Myopia Treatment Is Best for Your Child?

If your child's glasses prescription keeps getting stronger every year, you are not alone — and you are right to be concerned. Childhood myopia (nearsightedness) is not just a vision problem. It is a progressive condition, and the higher a child's final prescription becomes, the greater their lifetime risk of serious eye disease as an adult. The good news is that optometry has changed dramatically in the past decade. We now have three evidence-based tools to slow myopia progression, and in many cases we can combine them for an even stronger effect.

This guide compares the three modern options — orthokeratology (Ortho-K), low-dose atropine, and MiSight 1 day soft contact lenses — so you can walk into your consultation informed and ready to decide. At EyeCare Center of Orange County, Dr. Alexander Bonakdar personally designs every myopia management plan, and no two children get the same plan by default.

Why Your Child's Myopia Matters Beyond Glasses

A pair of glasses or regular contact lenses corrects blurry distance vision, but they do nothing to slow the eye's progressive elongation. As a myopic eye grows longer, the retina is stretched thinner, the optic nerve head is pulled and remodeled, and the entire structural integrity of the eye changes. These changes are permanent.

Higher levels of myopia carry meaningful adult-onset risks:

• Retinal detachment — risk rises sharply with axial length and degree of myopia
• Myopic maculopathy — progressive damage to the central retina, a leading cause of irreversible vision loss in high myopes
• Open-angle glaucoma — more common in myopic eyes, and often diagnosed later because of atypical optic nerve appearance
• Early and more visually significant cataracts
• Posterior staphyloma — outpouching of the back of the eye seen in pathologic myopia

The goal of modern myopia management is not just to give your child clear vision today. It is to keep that final prescription as low as possible so the adult eye is structurally healthier for the next 70 or 80 years.

The 3 Evidence-Based Options Today

Three interventions have strong clinical evidence for slowing myopia progression in children:

1. Orthokeratology (Ortho-K) — custom rigid lenses worn only at night
2. Low-dose atropine eye drops — a single drop each evening at bedtime
3. MiSight 1 day soft contact lenses — FDA-approved daily disposable soft lenses worn during waking hours

Each works through a different biological mechanism, which is why combining them sometimes produces better results than any single therapy. Here is how to think about each one.

A quick note on what the evidence base actually looks like: large landmark trials — including the CLEERE (Collaborative Longitudinal Evaluation of Ethnicity and Refractive Error) study, the BLINK (Bifocal Lenses In Nearsighted Kids) study, and the LAMP study mentioned below — have shaped how optometrists think about progression risk factors, optical interventions, and pharmacological approaches. We rely on this published evidence, not marketing claims, when we counsel families at the consultation.

Option 1: Orthokeratology (Ortho-K)

How It Works

Ortho-K lenses are custom-designed rigid gas permeable lenses that your child wears only while sleeping. Overnight, the lens gently reshapes the front surface of the cornea. In the morning, your child removes the lens and has clear, unaided vision all day — no glasses, no daytime contacts. The reshaping is temporary and fully reversible: if a child stops wearing the lenses, the cornea returns to its original shape within days to weeks.

Beyond the daytime vision benefit, Ortho-K produces a specific optical effect called peripheral myopic defocus. The reshaped cornea focuses light from the peripheral visual field in front of the peripheral retina, which is believed to send a "stop growing" signal to the eye. This is the proposed mechanism by which Ortho-K slows axial elongation.

Who It's For

• Children roughly age 7 and older with responsible at-home hygiene (parents handle insertion/removal and cleaning)
• Myopia generally in the −0.75 to −6.00 diopter range, with low to moderate astigmatism
• Active kids — swimmers, gymnasts, soccer players — who benefit from not having to manage glasses or contacts during the day
• Families who prefer a drug-free approach

Efficacy

Multiple peer-reviewed studies, including the landmark ROMIO, LORIC, and SMART trials, have shown Ortho-K slows axial eye growth in children compared to single-vision glasses or soft contact lenses. Published meta-analyses suggest roughly a ~50% reduction in progression on average over multi-year follow-up, though individual response varies. Ortho-K is generally considered one of the strongest single-therapy options for myopia control. Common branded Ortho-K designs include Paragon CRT and Euclid Emerald, both FDA-approved for overnight corneal reshaping. Newer high-add Ortho-K designs deliver a stronger peripheral myopic defocus signal and may produce better progression control in children who are progressing faster than average on a standard design.

Safety Profile

The main safety concern with any overnight contact lens is microbial keratitis — corneal infection. Studies in pediatric Ortho-K populations place this risk at a low rate comparable to other overnight contact lens wear, and it is highly preventable with strict hygiene: handwashing before handling lenses, using only the prescribed cleaning solutions, never rinsing or storing in tap water, and attending every scheduled follow-up. Parents who commit to the hygiene protocol have an excellent safety record.

Daily Life

Your child puts the lenses in at bedtime, sleeps normally, removes them in the morning, and has clear vision all day. There is an adjustment period of one to two weeks during which vision stabilizes. Most kids adapt within a few nights.

Option 2: Low-Dose Atropine Eye Drops

0.01%, 0.025%, and 0.05% — What's the Difference?

Atropine has been used in eye care for over a century, but for myopia control, we use extremely diluted concentrations. The major randomized trial in this space is the LAMP (Low-Concentration Atropine for Myopia Progression) Study, which directly compared 0.01%, 0.025%, and 0.05% in children.

• 0.01% — the mildest concentration; minimal side effects but somewhat less potent progression control
• 0.025% — intermediate concentration; a balanced profile
• 0.05% — the most effective of the three tested; slightly more side effects in some children

Atropine at these low concentrations is used off-label for myopia management in the United States — there is no FDA-approved atropine product specifically labeled for myopia control. However, it is widely used by optometrists and ophthalmologists worldwide based on strong published evidence, and the drops are prepared by compounding pharmacies to precise concentrations.

How It Works

The exact mechanism is still being studied, but atropine appears to act on receptors in the retina and sclera that regulate eye growth. Unlike Ortho-K, atropine does not rely on any optical effect — it is a pharmacological intervention. That is why atropine can be combined with glasses, soft contacts, Ortho-K, or MiSight lenses.

Efficacy

In the LAMP Study, 0.05% atropine produced meaningfully better slowing of progression than 0.01% over two to three years of follow-up. Longer-term data continues to accumulate. Atropine tends to work consistently across a range of myopia severities, including children with higher prescriptions who may be harder to fit in Ortho-K.

Side Effects

• Mild pupil dilation — more noticeable at 0.05% than 0.01%; some children experience light sensitivity outdoors and may benefit from photochromic (transitions) lenses
• Slight near blur — typically minor at 0.01%, more noticeable at higher concentrations; most children adapt without issue
• Occasional rebound — when drops are stopped, some children show a brief acceleration before settling

Cost

Low-dose atropine is typically the most affordable of the three options on a monthly basis because it is covered as a compounded medication. It does not usually require the same specialty lens fitting fees that Ortho-K and MiSight involve.

Option 3: MiSight 1 Day Daily Disposable Soft Lenses

FDA Approval Background

In November 2019, MiSight 1 day (CooperVision) became the first and only soft contact lens FDA-approved for the control of myopia progression in children ages 8 to 12 at the start of treatment. This approval was based on a rigorous multi-year randomized clinical trial and represented a meaningful milestone for pediatric eye care in the United States.

How It Works

MiSight lenses use a concentric ring design called ActivControl Technology. The center of the lens corrects your child's myopia for clear distance vision, while alternating treatment zones create peripheral myopic defocus — the same optical cue discussed in the Ortho-K section. By wearing the lenses during waking hours, the eye receives this growth-slowing signal throughout the day.

Who It's For

• Children ages 8 to 12 at the start of treatment (the FDA-indicated age range)
• Myopia generally up to about −6.00 diopters with low astigmatism
• Kids who want the experience of a daily disposable soft contact lens — fresh lens every morning, discarded every night, no cleaning or cases
• Families who prefer a daytime wear schedule over overnight lenses

Efficacy

The MiSight 3-year clinical trial, with follow-up extending through 6 and 7 years in subsequent reports, demonstrated significant slowing of both refractive progression and axial elongation compared to children wearing standard single-vision soft lenses. Longer-term extension data continues to support durability of the effect.

Convenience Factor

Because MiSight is a daily disposable, there is no cleaning, no solution, no case, and no long-term lens to lose or damage. A fresh, sterile pair each morning lowers infection risk compared to reusable soft lenses. Many families find this simplicity ideal for a first-time contact lens wearer.

Combining Therapies

One of the most important developments in modern myopia management is the recognition that combining therapies can outperform any single approach. Because atropine and optical interventions (Ortho-K or MiSight) work through different mechanisms, layering them is often synergistic rather than redundant.

Common combinations we consider:

• Ortho-K + low-dose atropine — particularly for rapid progressors or children whose progression continues despite Ortho-K alone
• MiSight + low-dose atropine — for daytime-wear families who need additional pharmacological support
• Specialty soft multifocal contacts + atropine — used in select cases where MiSight is not a fit

Combination therapy adds modest cost but can meaningfully reduce the final adult prescription for a fast-progressing child — which is the entire point of myopia management.

How We Decide Together at Your Consultation

There is no universally "best" option — only the best option for a specific child and family. At your consultation, Dr. Bonakdar will walk through:

• Your child's age and maturity — younger children often start with atropine; older, more responsible children may jump straight to Ortho-K or MiSight
• Current prescription and rate of progression — faster progressors often need more aggressive or combined therapy
• Axial length measurement — we measure the actual length of the eye, not just the prescription, which is the most important biomarker
• Corneal shape and tear film — Ortho-K has fitting requirements; dry eye can affect soft lens comfort
• Lifestyle — swimmers and athletes often favor Ortho-K; reading-heavy kids may prefer MiSight
• Parent preferences and budget — this is a family decision, not a solo clinician decision
• Compliance realism — atropine requires one drop at bedtime every day; soft lens success requires a child who can handle daily insertion

The plan we design is not static. We monitor progression every six months and adjust — swap concentrations, add a therapy, change lens designs — based on measurable results.

The Cost Reality

Myopia management is a specialty service that is generally not covered by vision insurance, though medical insurance sometimes reimburses portions depending on the diagnosis and plan.

Our Myopia Management program is priced as follows:

• $4,600 for a 2-year program — includes the initial evaluation, all specialty lens fittings (Ortho-K or MiSight), follow-up visits every 3 to 6 months, axial length measurements, and adjustments to the treatment plan
• $1,100 per year after the initial 2 years — for continued monitoring and lens updates as your child grows

Atropine drops are priced separately because they are dispensed by a compounding pharmacy and are typically the most affordable component of a plan.

Financing is available: we offer 12- or 24-month interest-free financing, and we accept CareCredit. Most families choose the 24-month plan to spread the cost across the treatment period.

What Won't Slow Myopia

Be cautious of approaches that sound like myopia control but are not evidence-based:

• Regular single-vision glasses — correct vision but do not slow progression
• Single-vision soft contact lenses — same limitation as single-vision glasses
• Blue-light blocking glasses — no published evidence that they slow myopia progression
• Vision therapy alone — excellent for binocular vision disorders, but not a myopia control strategy
• "Eye exercises" marketed to reverse myopia — there is no peer-reviewed evidence that any exercise regimen reverses or halts axial elongation

There is one lifestyle intervention with real evidence behind it: more time outdoors — roughly two hours per day of outdoor time has been associated with a lower risk of developing myopia and, to a lesser extent, slower progression once it has started. We encourage every myopic child to spend more time outside, regardless of which treatment option the family chooses.

Getting Your Child Started

The most important factor in myopia management is starting early. Every year of progression adds diopters to the final adult prescription, and those diopters carry lifelong disease risk. If your child's prescription has changed in the past year — or if you are the parent of a myopic child and no one has ever discussed axial length or progression control with you — now is the time for a consultation.

Schedule a myopia management consultation with Dr. Bonakdar by calling (949) 323-3600. We will measure your child's current myopia, assess axial length, review progression history, and build a plan that fits your child, your family, and your budget.

Related reading: Ortho-K for Adults · Scleral Lens Specialty Fitting · Orthokeratology Landing Page